April 2024 Newsletter
New Animal Models Humanized Immune-Checkpoint Mice Product Catalog Number B-hCRTAM mice 112532 B-hCD28/hGPC3 mice 113297 B-hMICB mice 112152 B-hRAGE mice plus 113157 B-hCD3E/hCD79B mice 113312…
Read more
Biocytogen’s Antibody Partner Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024
On April 7, at AACR, our therapeutic antibody collaborator Syncromune delivered an oral presentation unveiling clinical data of its SYNC-T technology for the first time!…
Read more
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates
Beijing, China, March 25, 2024 --Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel…
Read more
Biocytogen Symposium 2024: New Targets, New Therapeutics
[embed]https://youtu.be/TPV_3gMmUvE?si=qgqV-_b_0euuhL5I[/embed] Thanks to all who joined us at the 2024 Biocytogen Symposium! Your participation made this event a tremendous success. Whether you joined us in person or…
Read more
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
Beijing, China, February 19, 2024 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announces an antibody evaluation and option agreement with Gilead Sciences,…
Read more
Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development
Beijing, China – January 23, 2024 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced the launch of a new sub-brand, RenBiologicsTM, to…
Read more
Dr. Yuelei Shen Shared His Insights During Investment Reports/Newsweek Interview
Source: Investment Reports This interview, together with other interviews with the industry’s leading figures, will be published in the second edition of The New Era…
Read more
Biocytogen’s YH008 Greater China Licensee Chipscreen NewWay Announces First-Patient-In for Bispecific Antibody NWY001, a Next-Gen Tumor Immunotherapy
Beijing, China, January 5, 2024 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) partner Chipscreen NewWay Biosciences (“Chipscreen NewWay”) achieved first-patient-in for a phase…
Read more
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma
BEIJING, China and BOSTON, Massachusetts, USA---Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics,…
Read more
Manhattan BioSolutions Enters into Evaluation and Potential Licensing Agreement with Biocytogen for Use of Innovative Antibodies in Targeted Therapies
New York City, New York and Beijing, China, January 3, 2023 – Manhattan BioSolutions, Inc. (Manhattan Bio or MABS), an emerging biotech company developing innovative…
Read more